IN2014CN00570A - - Google Patents

Info

Publication number
IN2014CN00570A
IN2014CN00570A IN570CHN2014A IN2014CN00570A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A IN 570CHN2014 A IN570CHN2014 A IN 570CHN2014A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A
Authority
IN
India
Prior art keywords
therapy regimen
panitumumab
cetuximab
therapy
mutation
Prior art date
Application number
Other languages
English (en)
Inventor
Viladot Clara Montagut
Mestres Joan Albanell
Guerin Ana Rovira
Paricio Beatriz Bellosillo
Massegú Alba Dalmases
Original Assignee
Fundació Inst Mar Dinvestigacions Mèdiques Imim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst Mar Dinvestigacions Mèdiques Imim filed Critical Fundació Inst Mar Dinvestigacions Mèdiques Imim
Publication of IN2014CN00570A publication Critical patent/IN2014CN00570A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN570CHN2014 2011-08-03 2012-08-02 IN2014CN00570A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (fr) 2011-08-03 2011-08-03 Mutations du gène du récepteur de facteur de croissance épidermique
PCT/EP2012/065090 WO2013017645A1 (fr) 2011-08-03 2012-08-02 Mutations dans le gène du récepteur du facteur de croissance des cellules épidermiques

Publications (1)

Publication Number Publication Date
IN2014CN00570A true IN2014CN00570A (fr) 2015-04-03

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN570CHN2014 IN2014CN00570A (fr) 2011-08-03 2012-08-02

Country Status (12)

Country Link
US (1) US9765399B2 (fr)
EP (3) EP2554551A1 (fr)
JP (1) JP6149034B2 (fr)
KR (1) KR20140072035A (fr)
CN (1) CN103717616B (fr)
AU (1) AU2012292024A1 (fr)
BR (1) BR112014002373A2 (fr)
CA (1) CA2842270C (fr)
ES (1) ES2556468T3 (fr)
IN (1) IN2014CN00570A (fr)
RU (1) RU2014107908A (fr)
WO (1) WO2013017645A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2015175705A1 (fr) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Mutations géniques et altérations du nombre de copies de egfr, kras et met
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
JP6905464B2 (ja) * 2014-07-28 2021-07-21 フンダシオ インスティトゥ マー ディンヴェスティガシオンズ メディクー(イーエメイーエメ) 上皮増殖因子受容体遺伝子の細胞外ドメインiii内の変異
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
EP3286219A1 (fr) * 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558753A1 (fr) 2004-03-01 2005-09-15 University Of Chicago Polymorphismes du promoteur du gene du recepteur du facteur de croissance epidermique
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2601936C (fr) * 2005-02-24 2014-06-17 Amgen Inc. Mutations de recepteur de facteur de croissance epidermique
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
JP5596975B2 (ja) * 2006-10-26 2014-10-01 ジェネンテック, インコーポレイテッド 腫瘍と関連している遺伝的変異
CA2675362A1 (fr) 2007-01-18 2008-07-24 University Of Southern California Polymorphismes dans la voie de signalisation de l'egfr en tant que marqueurs pour le traitement du cancer
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
EP3216874A1 (fr) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Procédés pour la stratification et l'annotation des options de traitement médicamenteux contre le cancer

Also Published As

Publication number Publication date
BR112014002373A2 (pt) 2017-02-21
CA2842270A1 (fr) 2013-02-07
RU2014107908A (ru) 2015-09-10
EP2554551A1 (fr) 2013-02-06
AU2012292024A1 (en) 2014-02-27
WO2013017645A1 (fr) 2013-02-07
JP2014521342A (ja) 2014-08-28
KR20140072035A (ko) 2014-06-12
EP2739648A1 (fr) 2014-06-11
US9765399B2 (en) 2017-09-19
US20140170662A1 (en) 2014-06-19
CN103717616A (zh) 2014-04-09
JP6149034B2 (ja) 2017-06-14
EP2739648B1 (fr) 2015-09-16
CN103717616B (zh) 2016-06-29
ES2556468T3 (es) 2016-01-18
EP2995623A1 (fr) 2016-03-16
CA2842270C (fr) 2019-10-29

Similar Documents

Publication Publication Date Title
BR112014002373A2 (pt) mutações no gene do receptor do fator de crescimento epidermal
IL265478A (en) Measurement of protein expression using reagents with barcoded oligonucleotide sequences
WO2013022786A3 (fr) Biomarqueurs micro-arn
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX2014001377A (es) Metodo para detectar cancer pancreatico.
ZA201301307B (en) Method for testing reheating crack sensitivity of dissimilar steel
EP3044323A4 (fr) Compositions et méthodes de détection et de quantification d'une protéine cellulaire hôte dans des lignées cellulaires et polypeptides recombinés
GB201313477D0 (en) Nanopore biosensors for detection of proteins and nucleic acids
WO2011106738A3 (fr) Utilisation de clonotypes tcr en tant que biomarqueurs de maladie
WO2013160315A3 (fr) Prédicteurs génétiques de réponse à un traitement avec des antagonistes de crhr1
MX2014016036A (es) Sistemas, metodos y equipo para determinar la presencia de fluidos de interes.
EP4563709A3 (fr) Méthodes et matériaux pour évaluer le déséquilibre allélique
WO2013181576A3 (fr) Méthodes d'évaluation et de fabrication de produits biologiques
AU2012236134A8 (en) Biomarkers for predicting sensitivity to cancer treatments
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
PH12015501778A1 (en) Markers associated with wnt inhibitors
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
WO2012162613A3 (fr) Détection de variants de séquence dans le gène du récepteur du facteur de croissance épidermique humain (r-egf)
WO2012137180A3 (fr) Biomarqueurs d'efficacité d'immunothérapie
SG10201907690TA (en) Device and method for detecting target molecules
WO2015077342A3 (fr) Détection de la méthylation de l'arginine de l'egfr permettant de prédire la résistance à une thérapie
WO2011116209A3 (fr) Utilisation d'épitopes de phage à des fins de profilage de la réponse immunitaire
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2010144808A3 (fr) Identification de dsg-3 en tant que biomarqueur pour la détection de métastases dans les ganglions lymphatiques